October 28, 2005 – ChironAnnounces Promising Data from Clinical Study of Adjuvanted AvianInfluenza Vaccine; Results Confirm Previous Clinical Studies: Chiron’sMF59 Adjuvant Significantly Enhances Immune Response – Chiron Corporation via http://finanzen.net– “With more than 20 million doses of MF59-adjuvanted vaccine distributed outside of the United States for seasonal vaccination, we have built an impressive safety database. In addition, our previous clinical studies of a vaccine designed to protect against H5 avian influenza have demonstrated the potential of our adjuvant to reduce the required dose of antigen and to cross-protect against arange of related viral strains.”
COMMENT: This is a novel adjuvant…..maybe alumunium….but other news reports are very secretive about the “substance” that has been added to the vaccine. Stay tuned….
July 28, 2006: The West Australian GSK, the biggest drugs maker in Europe, said tests of its vaccine for H5N1 bird flu showed more than 80 per cent of volunteers dosed with 3.8mg of its active ingredient got a strong immune response. GlaxoSmithKline said it identified and patented a substance that boosts the vaccine’s effectiveness about a 20th of the current dose, which could stretch the scarce supply of vaccines about 20-fold.
July 4, 2006 – Title: Nontoxic mucosal adjuvant (patent) – Chiron SRL (Siena, IT) via www.pharmcast.com – “The present invention relates to an adjuvant useful for the administration of vaccines to organisms. In particular, the adjuvant of the invention allows the delivery of vaccines to mucosal surfaces to raise a secretory and systemic immune response.”
COMMENT: Breaking all the rules, WHO officials now say that nearly “any flu shot will do” to protect from bird flu….Doesn’t have to be a match, doesn’t even have to be close. Just give them a shot…any shot….Until we can get the mega-shot that will cover everything. For those of you who have never read Michael Palmer’s book, FATAL, now might be a good time to do so.
“People are taking pre-pandemic vaccination seriously,” says Derek Smith at the University of Cambridge. In May, a meeting of scientists and manufacturers at the World Health Organization in Geneva, Switzerland, recommended the development of vaccines that could be used to inoculate people before a pandemic takes hold.
These, they said, must have long-lasting effects, and be “broad-spectrum” enough to work against whatever pandemic virus emerges. Several novel vaccines that do both are now close to testing in humans. They include the addition of immunity-stimulating chemicals called adjuvants, vaccines made of DNA instead of the virus itself, and perhaps the ultimate – a vaccine that protects against every kind of flu.
COMMENT: Novel vaccine, using a topical adjuvant….anything to get the stuff in our bodies!
June 16, 2006: New Scientist News – Today’s bird flu vaccines will have to do The problem with powerful adjuvants is that they tend to be toxic. One company, however, says it has found a way around this. Iomai of Gaithersburg, Maryland, uses enterotoxins produced by E. coli bacteria, which are applied via a skin patch placed over the vaccine injection site. From there they pass directly into dendritic cells, a type of immune cell in the skin.
COMMENT: The only adjuvant approved for human use in the US is aluminum; they have started using MF59 in flu shots in Europe. With the rampant epidemic of allergies in the US, here is admitted PROOF that it is coming from vaccines.
April 23, 2006: BioSante reports promising results on bird-flu drug – MarketWatch “The problem with most adjuvants is that they can cause allergies,” said Simes. “Ours might not be as potent as others, but it is safer.” Because of this, Simes said, BioSante hopes to eventually partner with one of the major pharmaceutical firm working on an avian-flu vaccine to create a combination product.
COMMENT: This type of information lays the ground work for adding adjuvants such as M-59.
March 29, 2006: Bird flu vaccine only works at highest dose: study – Boston.com
The vaccine, made by a unit of Sanofi-Aventis and based on an H5N1 virus that killed a Vietnamese man in 2004, only produced a satisfactory immune response in volunteers at two doses of 90 micrograms each. That is 12 times what is needed for the annual seasonal flu shot.
COMMENT: All oil-based adjuvants have been associated with serious health problems, including lupus and arthritis. I highly recommend the book, Vaccine A: The Covert Government Experiment That’s Killing Our Soldiers–And Why GI’s Are Only The First Victims (Hardcover) for the full story on the toxic adujvants planned for the pandemic vaccine.
February 20, 2006 – Shark livers, aluminum salts tried in flu-vaccine recipes – Washington Post via Journal Gazette via www.fortwayne.com – “Adjuvants make small doses of vaccine act big. They focus the immune system’s attention on the ‘antigen’ “the substance that stimulates the protective effect. Some adjuvants even broaden immunity and make it longer-lasting. Scientists do not know exactly how adjuvants do all this. But they do know they make it possible to dilute a vaccine with no loss of effect…’The global demand for pandemic vaccines will be immense,’ said David Fedson, a physician, epidemiologist and former consultant to the World Health Organization. The only way to meet the demand, he believes, ‘is to use an adjuvant.’
COMMENT: MF-59 has been trialed in several influenza vaccines.
Guidice, GD, Hilbert AK, Bugarini R, Minutello A, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006 PMID: 16464520
Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC.Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet.2001 June 16;357(9272):1937-43. PMID: 11425416
Podda, A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001 Mar 21;19(17-19):2673-80. PMID: 11257408
Gasparini R, Pozzi T, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.Eur J Epidemiol. 2001;17(2):135-40. PMID: 11599686
COMMENT: Chiron is really excited about their adjuvant. Do they make a medicine for arthritis or lupus? –ST
February 12, 2006: Researchers Try to Boost Supply of Flu Vaccin “We are in possession of one of the key ingredients of a potential solution to the pandemic threat,” said Howard Pien, president of Chiron Corp. The California biotech firm has an
adjuvant, an emulsion called MF59 whose main constituent is shark-liver oil. It is already in use in a flu vaccine in Europe. “We believe that the adjuvant may become the holy grail of vaccines,” Chrystyna Bedrij, an analyst with Griffin Securities, wrote in November in a review of avian flu-related business.
COMMENT: Two experiments at the same time: experimental vaccine and an experimental adjuvant. Risky business.
January 26: (Reuters) GlaxoSmithKline Glaxo: Additive May Raise Pandemic Flu Vaccine Supply Plc is accelerating development of a novel additive for its experimental vaccine against H5N1 bird flu in humans that could help stretch supplies in the event of a pandemic.
COMMENT: This compound, Tween80, is part of the adjuvant MF59 and is also found in the following vaccines: DTaP (Infanrix), DTap (Tripedia), DTaP/Hib (TriHIb), DTaP/HepB/IPV (Pediarix), HepA/HepB (Twinrix)
December 23, 2005: IngentaConnect Polysorbate 80 in medical products and nonimmunologic anaphylacto… Polyoxyethylene-sorbitan-20-monooleate (also known as polysorbate 80 and Tween 80) is a solubilizing agent ubiquitously used in nutritives, creams, ointments, lotions, and multiple medical preparations (eg, vitamin oils, vaccines, and anticancer agents) and as an additive in tablets.
Conclusions: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.
Comment: This is the adjuvant under consideration: MF59
ScienceDirect – Biomedecine & Pharmacotherapy : Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine